The hypothalamo‐pituitary‐gonadal axis was studied in 12 young women with manic‐depressive or psychotic symptoms which obviously fluctuated in association with the menstrual cycle, and also in 36 psychiatric patients with other diagnoses. The hormonal features frequently observed among these 12 cases were elevated basal LH (8 of 12 cases), decreased basal FSH (6 of 12), elevated serum testosterone (6 of 12), androstenedione (5 of 12) and/or dehydroepiandrosterone‐sulfate (3 of 11). These abnormalities resemble those of polycystic ovary syndrome (PCOS). An ultrasonographical study revealed polycystic changes in 8 out of the 12 cases. In 10 cases clomiphene citrate was administered, and was effective in 8. In comparison with the pathophysiology of PCOS, a possible relationship was suggested between the psychiatric problems and the PCOS‐like hormonal abnormalities in these cases.
We report a rare case of anti-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) encephalitis presenting clinical relapse in association with recurrence of thymoma. Anti-AMPAR encephalitis is an autoimmune-mediated neurological disease, frequently accompanied by the presence of neoplasms, thus comprising the spectrum of paraneoplastic syndrome. A patient had been in remission for 34 months showed clinical relapse 3 months after the detection of recurrent thymoma. Clinical relapse of anti-AMPAR encephalitis after the recurrence of an initially detected neoplasm has not been previously reported. Our case therefore highlights the pathogenic relevance of specific tumor antigens as a trigger of anti-AMPAR antibody production and induction of the disease.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.